Skip to Content
Merck
CN

Key Documents

View All Documentation

L106

Loxapine succinate salt

solid

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C18H18ClN3O · C4H6O4
CAS Number:
27833-64-3
Molecular Weight:
445.90
NACRES:
NA.77
PubChem Substance ID:
24277719
UNSPSC Code:
12352200
EC Number:
248-682-0
MDL number:
MFCD00069298
Form:
solid
Quality level:
100
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

form

solid

Quality Level

100

color

white

solubility

H2O: soluble

originator

Watson

SMILES string

CN(CC1)CCN1C2=NC3=C(C=CC=C3)OC4=C2C=C(Cl)C=C4.OC(CCC(O)=O)=O

InChI

1S/C18H18ClN3O.C4H6O4/c1-21-8-10-22(11-9-21)18-14-12-13(19)6-7-16(14)23-17-5-3-2-4-15(17)20-18;5-3(6)1-2-4(7)8/h2-7,12H,8-11H2,1H3;1-2H2,(H,5,6)(H,7,8)

InChI key

YQZBAXDVDZTKEQ-UHFFFAOYSA-N

Gene Information

human ... DRD2(1813), DRD3(1814), DRD4(1815), HTR2A(3356), HTR2B(3357), HTR2C(3358), HTR7(3363)

Biochem/physiol Actions

D2/D4 dopamine receptor antagonist; 5-HT2A/2B, 5-H7 serotonin receptor antagonist; dibenzoxazepine antipsychotic agent.

Features and Benefits

This compound was developed by Watson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Regulatory Information

新产品

This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
BCCH0822
BCCG7141
BCBT9175
BCBP7940V
BCBN6090V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

[Progress through formulation].
Heike Oberpichler-Schwenk
Medizinische Monatsschrift fur Pharmazeuten, 36(7), 243-243 (2013-08-01)
Robert H Howland
Journal of psychosocial nursing and mental health services, 50(1), 16-18 (2012-01-11)
Acute agitation in patients with schizophrenia or bipolar disorder is an important clinical management problem. Liquid concentrates, orally disintegrating tablets, and/or intramuscular formulations of several second-generation atypical antipsychotic drugs are available for treating acute agitation. Loxapine is an older first-generation
B L Roth et al.
Psychopharmacology, 120(3), 365-368 (1995-08-01)
The affinities of 13 atypical and 12 typical antipsychotic drugs for the cloned rat D4 dopamine receptor and the D4/D2 ratios were examined. Of the atypical antipsychotic drugs tested, only clozapine, risperidone, olanzapine, zotepine and tiospirone had affinities less than
R T Owen
Drugs of today (Barcelona, Spain : 1998), 49(3), 195-201 (2013-03-26)
The treatment of acute agitation in psychiatric patients has traditionally involved the use of oral or intramuscular benzodiazepines, antipsychotics or their combination. However, oral medication may have too slow an onset and while the intramuscular route is faster, it carries
E Glusa et al.
British journal of pharmacology, 130(3), 692-698 (2000-05-24)
The endothelial 5-HT receptor mediating relaxation of pig pulmonary artery has been characterized using the selective 5-HT(2B) receptor agonist BW 723C86 and a variety of structurally diverse 5-HT receptor antagonists. If arterial rings with intact endothelium were precontracted with prostaglandin
View All Related Papers

Global Trade Item Number

SKUGTIN
L106-100MG04061832091679
L106-500MG04061833949214

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service